Mar­ket­ingRx roundup: Aduhelm can’t get trac­tion with docs; Pfiz­er press­es vac­cine ef­fort dur­ing NFL play­offs

While much of the phar­ma in­dus­try’s at­ten­tion piv­ot­ed to CMS’ pre­lim­i­nary de­ci­sion last week to on­ly cov­er Bio­gen’s con­tro­ver­sial Alzheimer’s drug Aduhelm in clin­i­cal tri­als and its ef­fect on pre­scrib­ing, neu­rol­o­gists were al­ready hes­i­tant.

Spher­ix Glob­al In­sights has been track­ing neu­rol­o­gists’ per­cep­tion of Aduhelm. Its lat­est six-month sur­vey, tak­en be­fore the CMS de­ci­sion, found that while now most neu­rol­o­gists have had in­ter­ac­tions with Aduhelm sales reps, the ma­jor­i­ty of neu­rol­o­gists are still not ac­tive­ly rec­om­mend­ing the drug.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER